Scientists test direct tumor injection in fight against advanced cancers
NCT ID NCT03010176
Summary
This early-stage study tested the safety and dosing of a new drug called ulevostinag, which is injected directly into tumors. It was tested alone and combined with the immunotherapy drug pembrolizumab in 156 people with advanced or spreading solid tumors or lymphomas. The main goal was to find a safe dose and understand side effects, while also checking if the treatment showed any early signs of helping shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center ( Site 0104)
Seoul, 05505, South Korea
-
Columbia University ( Site 0003)
New York, New York, 10032, United States
-
Henry Ford Health System ( Site 0014)
Detroit, Michigan, 48202, United States
-
Huntsman Cancer Institute ( Site 0004)
Salt Lake City, Utah, 84112, United States
-
Institut Claudius Regaud ( Site 0051)
Toulouse, Haute-Garonne, 31059, France
-
Institut Curie ( Site 0050)
Paris, 75005, France
-
Institut Gustave Roussy ( Site 0049)
Villejuif, Val-de-Marne, 94805, France
-
Mary Crowley Cancer Research Center ( Site 0001)
Dallas, Texas, 75230, United States
-
Mount Sinai Hospital ( Site 0002)
New York, New York, 10029, United States
-
Rambam Medical Center ( Site 0041)
Haifa, 3109601, Israel
-
Severance Hospital ( Site 0103)
Seoul, 03722, South Korea
-
Sheba Medical Center ( Site 0040)
Ramat Gan, 5265601, Israel
-
The Royal Marsden Foundation Trust ( Site 0031)
London, London, City of, SW3 6JJ, United Kingdom
-
The Royal Marsden NHS Foundation Trust. ( Site 0032)
Sutton, Surrey, SM2 5PT, United Kingdom
-
UCLA Medical Center ( Site 0005)
Santa Monica, California, 90404, United States
-
UCSF ( Site 0015)
San Francisco, California, 94158, United States
-
UPMC Hillman Cancer Center ( Site 0013)
Pittsburgh, Pennsylvania, 15232, United States
-
University of Alabama ( Site 0009)
Birmingham, Alabama, 35294, United States
-
University of California San Francisco ( Site 0007)
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.